Search results
Showing 201 to 223 of 223 results for myocardial infarction
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.
Excess winter deaths and illness and the health risks associated with cold homes (NG6)
This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Guide to the methods of technology appraisal 2013
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
NICE recommends life changing technology is rolled out to people with type 1 diabetes
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by NICE
How 'surrogate outcomes' influence long-term health outcomes
NICE working with international organisations to develop guidance
NICE has today (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.
Local government can reduce the impact of chronic illnesses and prevent premature mortality by effectively delivering NHS Health Checks, according to NICE.
NICE approves ground-breaking cholesterol-lowering drug inclisiran
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.
NICE recommends rivaroxaban to prevent blood clots in patients who have had a heart attack
Rivaroxaban (Xarelto), in combination with clopidogrel and aspirin, or with aspirin alone, can now be used as an option for preventing blood clots in people who have had an acute coronary syndrome, following latest guidance.
Offer cardiac rehabilitation 'as soon as possible' to heart attack patients
Cardiac rehabilitation should be offered as soon as possible to people who have had an myocardial infarction (MI) to help them get back to everyday life as quickly as possible, says NICE.
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.
Statins should be offered to everyone who has chronic kidney disease, says NICE
Healthcare professionals should offer statins to millions of people with chronic kidney disease (CKD). This will help to manage their increased risk of cardiovascular disease (CVD), says NICE.
NICE wants people who show signs of sepsis to be treated with the same urgency given to those with suspected heart attacks.
Three new treatment options for type 2 diabetes recommended by NICE
Tens of thousands of people with type 2 diabetes will be eligible for new treatments under new guidance from NICE.
Speaking with one language: How using a common data model might speed up decision making
NICE is taking part in the European Health Data and Evidence Network (EHDEN) project, which is exploring the use of common data models for healthcare research. This could support faster patient access to innovative medicines in areas of unmet need.